RT Journal Article
SR Electronic
T1 Cost-effectiveness of a whole-area testing pilot of asymptomatic SARS-CoV-2 infections with lateral flow devices: A modelling and economic analysis study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.10.21256816
DO 10.1101/2021.05.10.21256816
A1 Mark Drakesmith
A1 Brendan Collins
A1 Angela Jones
A1 Kelechi Nnoaham
A1 Daniel Thomas
YR 2022
UL http://medrxiv.org/content/early/2022/03/08/2021.05.10.21256816.abstract
AB Background Mass community testing for SARS-CoV-2 by lateral flow devices (LFDs) aims to reduce prevalence in the community. However its effectiveness as a public heath intervention is disputed.Method Data from a mass testing pilot in the Borough of Merthyr Tydfil in late 2020 was used to model cases, hospitalisations, ICU admissions and deaths prevented. Further economic analysis with a healthcare perspective assessed cost-effectiveness in terms of healthcare costs avoided and QALYs gained.Results An initial conservative estimate of 360 (95% CI: 311-418) cases were prevented by the mass testing, representing a would-be reduction of 11% of all cases diagnosed in Merthyr Tydfil residents during the same period. Modelling healthcare burden estimates that 24 (16 - 36) hospitalizations, 5 (3-6) ICU admissions and 15 (11-20) deaths were prevented, representing 6.37%, 11.1% and 8.2%, respectively of the actual counts during the same period. A less conservative, best-case scenario predicts 2333 (1764-3115) cases prevented, representing 80% reduction in would-be cases. Cost effectiveness analysis indicates 108 (80-143) QALYs gained, an incremental cost ratio of £2,143 (£860-£4,175) per QALY gained and net monetary benefit of £6.2m (£4.5m-£8.4m). In the best-case scenario, this increases to £15.9m (£12.3m-£20.5m).Conclusions A non-negligible number of cases, hospitalisations and deaths were prevented by the mass testing pilot. Considering QALYs gained and healthcare costs avoided, the pilot was cost-effective. These findings suggest mass testing with LFDs in areas of high prevalence (>2%) is likely to provide significant public health benefit. It is not yet clear whether similar benefits will be obtained in low prevalence settings or with vaccination rollout.Competing Interest StatementDr Collins is seconded as Head of Health Economics in Welsh Government, this paper does not represent any views of Welsh Government.Funding StatementThis study was performed as part of our ongoing epidemic response and no external sources of funding were used. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was reviewed by the Public Health Wales Research and Development Office and determined to be usual practice in public health, and therefore did not require external NHS ethics committee approval. Investigation of communicable disease outbreaks and surveillance of notifiable disease is permitted under Public Health Wales Establishment Order. Data were held and processed under Public Health Wales information governance arrangements in compliance with the Data Protection Act, Caldicott Principles and Public Health Wales guidance on the release of small numbers. No data identifying protected characteristics of an individual were released outside Public Health Wales.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAggregated data on Covid-19 cases, hospitalizations and deaths is available on the Public Health Wales Rapid Covid-19 Surveillance Dashboard. Further anonymized data can be made available on reasonable request. https://public.tableau.com/profile/public.health.wales.health.protection#!/vizhome/RapidCOVID-19virology-Public/Headlinesummary